A Short Eulogy For The Rebate Rule
The rebate rule is dead, but we should pay tribute to the failed endeavor.
You may also be interested in...
White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.
CMS has abandoned its plan to give private plans more leverage in the “protected” drug classes in Part D. It will probably be a long time before anyone tries to change the protected classes again.
Committee Chair Maria Cantwell (D-Wash.) solicits advice from witnesses for additional authorities to conduct oversight of PBMs and pushes for a GAO study.